Abstract:Several aspects of EGFR TKI treatment have been discussed.The issue of TKIs resistance has been treated in some papers. In their Opinion, Bronte G et al discussed the topic of Osimertinib resistance and the possible combination strategies or the use of fourth generation EGFR-TKIs to overcome it. They supposed that in the next future oncologists will be able to address each patients who experience resistance to upfront osimertinib toward a different treatment strategy on the basis of molecular alterations highlighted by liquid biopsy or tumor biopsy. In this line, Carlo Bao et al presented two clinical cases harboring concomitant EGFR and BRAF alterations and treated with Osimertinib. Both cases were responsive to treatment and liquid biopsy results were in accordance with the clinical behaviour. Patients with advanced NSCLC with secondary T790M can benefit from Osimertinib, but the role of this drug in patients who exhibith resistance without T790M or with T790M unknown status is not well established. From the systematic review and meta-analysis performed by Yi XF and colleagues emerged that patients who undergo progression with brain metastasis on first or second generation TKIs can benefit from subsequent Osimertinib regardless T790M status. This represent an important finding that could orientate clinical decision management after Osimertinib resistance.Other types of resistance mechanisms are known, and the role of tumor-associated macrophages (TAMs) is also emerging (1). Previous studies have demonstrated that high infiltration of TAMs is significantly associated with an unfavorable prognosis in NSCLC patients treated with EGFR-TKIs (2). So, the inhibition of TAMs may a potential approach to improving resistance to EGFR-TKIs. In the review reported by Cheng D et al, a number of preclinical studies have been discussed, analysing the combination of EGFR-TKIs with several compound directed versus TAMs. In particular, inhibiting mTOR, AKT and STAT3 pathways, such as the lipid metabolic pathway, could all be possible potenatial strategies to overcome EGFR-TKI resistance.The addition of antiangiogenic treatments to EGFR-TKis was also studied. The systematic review and meta-analysis by Zheng H et al highlighted that the addition of bevacizumab to EGFR-TKI provide significant better PFS and OS, and the benefit is more evident for patients who have ever smoked, aged <75 years and of Asian population. Hsu PC and colleagues reported the results of a study in which first-line bevacizumab was combined with erlotinib or afatinib in EGFR-mutated NSCLC, demonstrating the development of T790M as resistance mechanism in 57.9% of cases. The addition of anti-angiogenic treatment in patients with an acquired resistance to Osimertinib was also demonstrated in a clinical case described by He W et al. In particular, a NSCLC patients harboring acquired EGFR 19Del/T790M/cis-C797S mutation resistance was treated with sintilimab, an anti-VEGF drug and chemotherapy. The patient remained progression-free for 15 months and the regimen was well tolerated. The addition of immunotherapy in EGFR-mutated patients is a controversial topic (3). Microsatellite instability is a rare event in NSCLC, but Yang M et al reported a case of apatients with a rare pulmonary enteric adenocarcinoma with EGFR mutation and MSI-H, who receive benefit from a combination approach of EGFR-TKI plus immune check point inhibitor.Rare EGFR mutations are another important issue object of several studies in the last years. It was reported that afatinib, an irreversible ErbB family inhibitor, is more efficacious in treating patients with uncommon EGFR mutations (4). Dong W et al performed a literature search on studies evaluating the efficacy of afatinib in any line of treatment in NSCLC patients with uncommon EGFR mutations. Their conclusion was that afatinib seems to be effective in patients with the more frequent uncommon EGFR mutations, whereas inconsistent data are present with regard to the other uncommon EGFR alterations, due to the high heterogeneity of them. Christopoulos P et al described seven clinical cases of patients carrying different uncommon EGFR mutations treated with afatinib. Overall, patients responded to afatinib, with six partial response and three durable responses. Interestingly, co-mutations did not preclude sensitivity to the drug, with durable response observed also in patients exhibiting cooccurring TP53 or CDKN2A mutations. Another case report was reported by Wang P et al, describing a patient carrying two exon 18 mutations and who acquired an EGFR amplification after treatment with osimertinib. The patient showed a partial response to neratinib. Also, a further case report of a patient carrying an EGFR kinase domain duplication was reported by Lin H and colleagues. The patient received the 3rd generation EGFR-TKI furmonertinib and obtained a partial response in primary tumor and in -Abstract Truncated-

Abivertinib in patients with T790M-positive advanced NSCLC and its subsequent treatment with osimertinib

Safety and Efficacy of Abivertinib (AC0010), a Third-Generation EGFR Tyrosine Kinase Inhibitor, in Chinese Patients with EGFR-T790M Positive Non-Small Cell Lung Cancer (NCSLC).

A novel third generation EGFR tyrosine kinase inhibitor Abivertinib for EGFR T790M mutant Non-Small Cell Lung Cancer: a multicenter phase1/2 study

A Modified Phase 1 Clinical Trial of Abivertinib (ac0010), a Third-Generation EGFR Tyrosine Kinase Inhibitor, in Chinese Patients with EGFR-T790M-positive Non-Small Cell Lung Cancer

A Novel Third-generation EGFR Tyrosine Kinase Inhibitor Abivertinib for EGFR T790M-mutant Non–Small Cell Lung Cancer: a Multicenter Phase I/II Study

Analysis of resistance mechanisms to abivertinib, a third-generation EGFR tyrosine kinase inhibitor, in patients with EGFR T790M-positive non-small cell lung cancer from a phase I trial

The Resistance Landscape of Abivertinib, a Third-Generation EGFR Tyrosine Kinase Inhibitor, and Clinical Strategy to Overcome Resistance in EGFR T790M-Positive Non-Small Cell Lung Cancer

Efficacy and Safety of Befotertinib (D-0316) in Patients with EGFR T790M-Mutated NSCLC That Had Progressed after Prior EGFR Tyrosine Kinase Inhibitor Therapy: A Phase 2, Multicenter, Single-Arm, Open-Label Study.

Editorial: Advances in the use of EGFR TKIs in the treatment of NSCLC

Third-line Treatment: A Randomized, Double-Blind, Placebo-Controlled Phase III ALTER-0303 Study—efficacy and Safety of Anlotinib Treatment in Patients with Refractory Advanced NSCLC.

Analysis of the Clinical Effect of Osimertinib on 90 Cases with Advanced Lung Adenocarcinoma

Afatinib plus bevacizumab combination after osimertinib resistance in advanced EGFR-mutant non-small cell lung cancer: Phase II ABCD-study

Survival benefit of osimertinib combination therapy in patients with T790M-positive non-small-cell lung cancer refractory to osimertinib treatment

Real-world Afatinib Outcomes in Advanced Non-small Cell Lung Cancer Harboring EGFR Mutations

Durable clinical benefit from afatinib in a lung adenocarcinoma patient with acquired EGFR L718V mutation-mediated resistance towards osimertinib: a case report and literature review

Osimertinib Efficacy and Safety in Treating Epidermal Growth Factor Receptor Mutation‐Positive Advanced Non–Small‐Cell Lung Cancer: A Meta‐Analysis

AUTOMAN: A phase Ib/IIa study of osimertinib combined with anlotinib in EGFRm, treatment-naive advanced NSCLC patients

Treatment of EGFR T790M-Positive Non-Small Cell Lung Cancer

Survival benefit of anlotinib in T790M‐positive non‐small‐cell lung cancer patients with acquired osimertinib resistance: A multicenter retrospective study and exploratory in vitro study

Successful Treatment of EGFR T790M-mutant Non-Small Cell Lung Cancer with Almonertinib after Osimertinib-Induced Interstitial Lung Disease: a Case Report and Literature Review

Abstract 3343: Durable response to osimertinib monotherapy as first line treatment in stage IVB lung adenocarcinoma with atypical EGFR L747P mutation